GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Unearned Premiums

Medivir AB (OSTO:MVIR) Unearned Premiums


View and export this data going back to 1996. Start your Free Trial

What is Medivir AB Unearned Premiums?

Unearned Premiums only applies to insurance companies.


Medivir AB Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.